Rodger Novak Sells 18,470 Shares of CRISPR THERAPTC (CRSP) Stock
CRISPR THERAPTC (NASDAQ:CRSP) CEO Rodger Novak sold 18,470 shares of the stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $20.76, for a total value of $383,437.20. Following the transaction, the chief executive officer now owns 1,148,007 shares in the company, valued at approximately $23,832,625.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Rodger Novak also recently made the following trade(s):
- On Wednesday, August 30th, Rodger Novak sold 75,795 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $20.25, for a total value of $1,534,848.75.
- On Thursday, June 22nd, Rodger Novak sold 10,825 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $15.37, for a total value of $166,380.25.
- On Wednesday, June 21st, Rodger Novak sold 30,222 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $15.01, for a total value of $453,632.22.
- On Friday, June 9th, Rodger Novak sold 5,303 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $15.02, for a total value of $79,651.06.
CRISPR THERAPTC (CRSP) opened at 18.47 on Thursday. CRISPR THERAPTC has a 12 month low of $11.63 and a 12 month high of $25.00. The firm’s 50-day moving average price is $18.43 and its 200-day moving average price is $17.80. The stock’s market cap is $749.72 million.
CRISPR THERAPTC (NASDAQ:CRSP) last issued its earnings results on Thursday, August 10th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.06. The company had revenue of $3.60 million during the quarter, compared to analyst estimates of $3.29 million. CRISPR THERAPTC had a negative net margin of 406.61% and a negative return on equity of 47.46%. The company’s revenue for the quarter was up 350.0% compared to the same quarter last year. On average, analysts predict that CRISPR THERAPTC will post ($2.43) earnings per share for the current year.
WARNING: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/07/rodger-novak-sells-18470-shares-of-crispr-theraptc-crsp-stock.html.
A number of brokerages have issued reports on CRSP. Cann began coverage on CRISPR THERAPTC in a research report on Monday, July 17th. They set a “market perform” rating on the stock. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of CRISPR THERAPTC in a research report on Tuesday, July 18th. SunTrust Banks, Inc. began coverage on CRISPR THERAPTC in a research report on Thursday, July 13th. They set a “hold” rating and a $16.00 price target on the stock. Finally, Chardan Capital reiterated a “buy” rating on shares of CRISPR THERAPTC in a research report on Monday, August 14th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $21.92.
Institutional investors have recently added to or reduced their stakes in the company. IHT Wealth Management LLC bought a new position in shares of CRISPR THERAPTC during the 1st quarter valued at $110,000. Wells Fargo & Company MN raised its holdings in shares of CRISPR THERAPTC by 459.7% during the 2nd quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after purchasing an additional 6,560 shares in the last quarter. ARK Investment Management LLC bought a new position in shares of CRISPR THERAPTC during the 2nd quarter valued at $206,000. Vanguard Group Inc. bought a new position in shares of CRISPR THERAPTC during the 2nd quarter valued at $273,000. Finally, Monashee Investment Management LLC raised its holdings in shares of CRISPR THERAPTC by 208.7% during the 1st quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock valued at $473,000 after purchasing an additional 15,000 shares in the last quarter. Institutional investors and hedge funds own 23.90% of the company’s stock.
About CRISPR THERAPTC
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Stock Ratings for CRISPR THERAPTC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR THERAPTC and related stocks with our FREE daily email newsletter.